Background: Liver is the main source of pseudocholinesterase. It is a non-specifi c cholinesterase found in the blood plasma and may be reduced in patients with advanced liver diseases. Measurement of serum pseudocholinesterase activity serves as a sensitive indicator of synthetic capacity of the liver and can be used as a prognostic marker for carcinoma. Objective: To study pseudocholinesterase activities in liver diseases. Method: A prospective study was conducted at College of Medical Sciences Teaching Hospital (CMS-TH), from May 2011 to May 2013 with 25 controls and 25 diagnosed cases each of carcinoma of liver, cirrhosis of liver, infective hepatitis and obstructive jaundice among both sexes of same age group attending medical outpatient and inpatient departments. Serum pseudocholinesterase and other liver function tests were performed with semi-autoanalyser and Roche Hitachi 902 respectively. Results: Pseudocholinesterase level was markedly decreased in carcinoma of liver (mean ± SD = 1369.48 ± 276.64 IU/L) followed by cirrhosis of liver (mean ± SD = 1735.16 ± 433.82 IU/L), infective hepatitis (mean ± SD = 3800.69 ± 764.17 IU/L), obstructive jaundice (mean ± SD = 5539 ± 791.05 IU/L) when compared with controls (mean ± SD = 6865.12 ± 928.41 IU/L). The difference in the means was statistically signifi cant (p <0.001). Conclusion: There was signifi cant decrease in pseudocholinesterase level in carcinoma of liver followed by cirrhosis of liver while less so in infective hepatitis. In obstructive jaundice the enzyme level was found to be decreased but higher than other liver diseases. The results indicated that with more severe liver cell destruction or cell degeneration, there was corresponding signifi cant decrease in the level of pseudocholinesterase, which could be used as diagnostic marker of liver disease.
INTRODUCTION
P seudocholinesterase (PChE) is also known as butyrylcholinesterase (BChE), serum cholinesterase, false cholinesterase or most formally acylcholineacylhydrolase. It is found in central and peripheral nervous system, kidney, intestine, pancreas and liver (hepatocytes) [1] [2] [3] . It is synthesized in liver and secreted into plasma mainly as a tetrameric glycoprotein 4, 5 . It can hydrolyse hydrophobic and hydrophilic carboxylic or phosphoric acid ester containing compounds 6 . It was so named due to its ability to hydrolyse butyrylcholine faster than other esters 7 . It has a half-life of about 12 days 1, [8] [9] [10] [11] . Its normal value ranges between 5,900 and 13,200 IU/L 12, 13 . The level of PChE measurement serve as a sensitive indicator of synthetic capacity of liver, any decrease in PChE activity refl ects impaired synthesis of enzyme by the liver 14 . Hepatocellular impairment will refl ect a decreased enzyme activity. In fact, plasma level falls in acute and chronic liver damage, cirrhosis, and liver metastases, being a biochemical marker of organ damage 11 . Physiologically, the function of this enzyme is unknown 4, 6, 15, 16 . A severe fulminant liver disease can end in death before the enzyme level shows a signifi cant fall 1 . A small proportion of healthy population is lacking in plasma BChE, due to a genotype aberration; studies carried out in Europe indicate a three to four percent prevalence of congenital serum BChE defi ciency subjects 11 . The aim of the present study was to investigate pseudocholinesterase as a probable prognostic marker in different liver disorders. This study is mainly focused on pseudocholinesterase and its activity in liver disorder.
METHODS
The present study was carried out at College of Medical Sciences Teaching Hospital, Bharatpur from May 2011 to May 2013. In the present study 25 healthy age and sex matched controls (staff and students) and 25 known cases each of carcinoma of liver, cirrhosis of liver, infective hepatitis and obstructive jaundice of both sexes between 20 to 70 years age group attending outpatient department and inpatient department were included. Serum pseudocholinesterase and other liver function tests were performed with semi-autoanalyser and Roche Hitachi 902 respectively in controls and cases. An increased activity of this enzyme has been reported in obesity, diabetes, uraemia, hyperthyroidism and hyperlipidaemic subjects 4, 12, 13 . Low plasma PChE levels have also been found in protein energy malnutrition, during stress and (chronic and acute) infl ammation 17 . So, patients with these cases were excluded from the study.
Pseudocholinesterase estimation is done by colorimetric 5, 5'-dithiobis-2-nitrobenzoate (DTNB) method using AMP diagnostics.
COLORIMETRIC METHOD
Cholinesterase hydrolyses butyrylthiocholine to butyrate and thiocholine. Thiocholine reacts with DTNB to form nitro-2-mercapto-5-benzoate, a yellow compound according to the following reaction. It is measured at 405 nm.
Butyrylthiocholine + H2O
Cholinesterase Butyrate +
The rate of nitro-2-mercapto-5-benzoato formation, measured photometrically, is proportional to the enzymatic activity of cholinesterase in the sample.
STATISTICAL ANALYSIS
Statistical analysis was done by SPSS (Statistical package for social science) version 15. Independent sample t-test was used to compare the means between different groups.
RESULTS
Gender and age distribution of cases and controls are shown in Table 1 and 2. In all disease groups, there was male predominance except in obstructive jaundice. Majority of patients belonged to age group 41 to 60 years. Decrease in pseudocholinesterase level was highest in carcinoma of liver (80%) followed by cirrhosis of liver (75%), infective hepatitis (45%) and obstructive jaundice (30%) respectively as shown in Table 3 . 
DISCUSSION
In the present study 25 normal controls and 100 cases suffering from hepatic diseases were included, comprising of 25 cases each of carcinoma of liver, cirrhosis of liver, infective hepatitis and obstructive jaundice. Pseudocholinesterase level was markedly decreased in carcinoma of liver (mean ± SD = 1369.48 ± 276.64 IU/L) followed by cirrhosis of liver (mean ± SD = 1735.16 ± 433.82 IU/L), infective hepatitis (mean ± SD = 3800.69 ± 764.17 IU/L), obstructive jaundice severely decreased in carcinoma of liver than infective hepatitis and cirrhosis of liver. So, one can infer therefore that, pseudocholinesterase reduces when the functional parenchymal cells are damaged or decrease, as liver synthesizes pseudocholinesterase. So, it has a survival predictive role in cancer patients and seems to correlate with disease progression. Regarding liver diseases, a decreased BChE activity refl ects hepatocellular impairment; similarly, recovery was evidenced by a gradual increase of BChE levels. In advanced liver cancer with or without hepatic involvement there is mild to moderate infl ammation and various degree of protein energy malnutrition resulting the level of pseudocholinesterase to decrease but in cirrhosis of liver pseudocholinesterase level would decrease very much when the number of functional parenchymal cells of liver decreases. Similarly in infective hepatitis the liver cells are damaged but hepatocytes are not decreased as compared to cirrhosis or carcinoma of liver 18, 21 . Similar fi nding were also found by S Venkata Rao et al (2011) 21 and also by MG Khan (1962) 22 .
The level of PChE (5539 ± 791.05 IU/L) in obstructive jaundice was decreased as compared to control (6865.12 ± 928.41 IU/L). The difference in the mean was statistically signifi cant (p <0.001) as shown in Figure 1 . The level of pseudocholinesterase was near to normal but little less in comparison to the controls but higher than other liver disorders. Such fi nding was also documented by S VenkataRao et al (2011) 21 . Similar fi nding was also reported by MG Khan (1962) 22 . Since, in obstructive jaundice the pathogenesis lies outside the liver and it is not due to the liver cell destruction or degeneration but due to obstruction either in right and left hepatic duct or in gall bladder or in cystic duct or in common bile duct, the reduction is less compared to other pathologies.
A study was conducted by Ogunkeye et al (2006) 11 , to evaluate if serum BChE activity could help in differentiating between liver and non-liver diseases, among three groups of subjects: group 1, liver disease with at least four out of fi ve abnormal liver function tests (aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase, total bilirubin, and albumin); group 2, non-liver disease with at least two abnormal liver function tests, and group 3, healthy subjects. Group 2 patients presented serum BChE activity within normal range for healthy individuals, but the mean BChE value was lower compared to the control group. However, the difference was not statistically signifi cant. On the other hand, patients with liver diseases (group 1) had serum BChE activity well below the reference interval for healthy subjects. The predominant hepatic source of serum BChE activity, the marked decreased synthesis with hepatocyte dysfunction, and its restoration with hepatocyte recovery suggested that serum BChE activity might be a more specifi c marker of liver dysfunction than the more traditional liver function tests.
CONCLUSION
The results indicate that with more severe liver cell destruction or degeneration, there was signifi cant decrease in the level of pseudocholinesterase. This study shows the important activities of pseudocholinesterase in differentiating different liver disorder. So, Serum PChE assessment should be included as a routine clinical diagnostic proced ure to evaluate patient prognostic value varying from different liver disorder. So, it can be used as a prognostic biomarker.
